Business
Renata Medical Announces CMS Approval of New Technology Add-On Payment (NTAP) for the Minima Stent System
NEWPORT BEACH, Calif., August 12, 2025--Renata Medical, a company dedicated to transforming care for children with congenital heart disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for the Minima Stent System under the Inpatient Prospective Payment System (IPPS) for Fiscal Year 2026, effective October 1, 2025.
About this update from Netapp, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/ea93200e74a83ca3cfa875ca7cd58eac"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jrGWLeITNv4Crfz__O3rFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ea93200e74a83ca3cfa875ca7cd58eac","width":480,"height":270}},"lazy":false},{"type":"text","content":"NTAP approval highlights Minima’s clinical significance and ensures hospital reimbursement for inpatient use beginning October 1, 2025","length":134,"tagName":"p"},{"type":"text","content":"NEWPORT BEACH, Calif., August 12, 2025--(BUSINESS WIRE)--Renata Medical, a company dedicated to transforming care for children with congenital heart disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for the Minima Stent System under the Inpatient Prospective Payment System (IPPS) for Fiscal Year 2026, effective October 1, 2025.","length":415,"tagName":"p"},{"type":"text","content":"The Minima Stent System is the first and only FDA-approved stent designed specifically for neonates, infants, and young children with native or post-surgical pulmonary artery stenoses or coarctation of the aorta. The NTAP designation recognizes Minima as a novel and clinically impactful technology that meets CMS’s stringent cost and clinical criteria.","length":353,"tagName":"p"},{"type":"text","content":"This NTAP approval serves not only as a powerful reimbursement win, but also as a rare and prestigious endorsement of the Minima Stent System’s meaningful impact on patient outcomes. With only a select number of technologies reaching this milestone each year, NTAP reflects the clinical value, innovation, and unmet need Minima addresses for the most vulnerable pediatric patients. It reinforces the importance of continued investment and leadership in congenital heart disease innovation.","length":489,"tagName":"p"},{"type":"text","content":"Under the ruling, CMS has finalized a maximum NTAP reimbursement of $22,685 per case. The approval follows Minima’s FDA premarket approval (PMA) on August 28, 2024, and its prior designation as a Breakthrough Device.","length":216,"tagName":"p"},{"t...